Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells

Cancer Research

Volumn 58, Issue 12, 1998, Pages 2661-2666

  Maurer Gebhard, Martina ^a   Schmidt, Mathias ^a   Azemar, Marc ^a   Altenschmidt, Uwe ^a   Stöcklin, Elisabeth ^a   Wels, Winfried ^a   Groner, Bernd ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA GALACTOSIDASE; HYBRID PROTEIN; ONCOPROTEIN; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; CARCINOMA, RENAL CELL; EXOTOXINS; FEMALE; GENE THERAPY; GENETIC ENGINEERING; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; VIRULENCE FACTORS;

EID: 0032526014     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Workman, P. New approaches in cancer pharmacology: drug design and development. In: U. Veronesi (ed.), Monographs, Vol. 2., pp. 7-22. Berlin/Heidelberg: Springer Verlag, 1994.
2. Hynes, N. E., and Stern, D. F. The biology of ErbB2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198: 165-184, 1994.
3. Peles, E., and Yarden, Y. Neu and its ligands: from an oncogene to neural factors. Bioessays, 15: 815-824, 1993.
4. erbB2-specific single chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int. J. Cancer, 60: 137-144, 1995.
5. Groner, B., Wels, W., and Hynes, N. E. The erbB-2 receptor as a target for directed tumor therapy. In: J. R. Pasqualini and B. S. Katzenellenbogen (eds.), Hormone Dependent Cancer, pp. 255-265. New York: Marcel Dekker Inc., 1996.
6. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddel, T., Henderson, I. C., and Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic beast cancer. J. Clin. Oncol., 14: 737-744, 1996.
7. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I., and King, C. R. Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 89: 5867-5871, 1992.
8. Pastan, I., and Fitzgerald, D. Recombinant toxins for cancer treatment. Science (Washington DC), 245: 1173-1177, 1991.
9. Wels, W., Harwerth, I. M., Müller, M., Groner, B., and Hynes, N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res., 52: 6310-6317, 1992.
10. Harwerth, I. M., Wels, W., Marte, B. M., and Hynes, N. E. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as a partial ligand agonists. J. Biol. Chem., 267: 15160-15167, 1992.
11. Wels, W., Harwerth, I. M., Zwickl, M., Hardman, N., Groner, B., and Hynes, N. E. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology, 10: 1128-1132, 1992.
12. Altenschmidt, U., Schmidt, M., Groner, B., and Wels, W. Targeted therapy of schwannoma cells in immunocompetent rats with an ErbB2-specific antibody-toxin. Int. J. Cancer, 73: 117-124, 1997.
13. Murphy, G. P., and Hrushesky, W. J. A murine renal cell carcinoma. J. Natl. Cancer Inst., 50: 1013-1025, 1973.
14. Hrushesky, W. S., and Murphy, G. P. Investigation of a new renal tumor model. J. Surg. Res., 15: 327-332, 1973.
15. Salupp, R. R., Sicker, D. C., Wolmark, N., Herberman, R. B., and Hakala, T. R. Chemoimmunotherapy of metastatic murine renal cell carcinoma using flavone acetic acid and interleukin 2. J. Urol., 174: 1120-1123, 1992.
16. Morita, T., Shinohara, N., and Tokue, A. Antitumor effect of a synthetic analogue of fumagillin on murine renal cell carcinoma. Br. J. Urol., 74: 416-421, 1994.
17. Buchner, J., Pastan, I., and Brinkmann, U. A. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem., 205: 263-270, 1992.
18. Williams, P. D., Pontes, E. J., and Murphy, G. P. Studies on the growth of a murine renal cell carcinoma and its metastatic patterns. Res. Commun. Chem. Pathol. Pharmacol., 34: 345-349, 1981.
19. Pai, L. H., and Pastan, I. Monoclonal antibodies in cancer therapy: immunotoxins and recombinant toxins. In: V. T. DeVita, S. Hellmann, and S. A. Rosenberg (eds.). Biologic Therapy of Cancer, pp. 521-533. Philadelphia: J. B. Lippincott Co., 1991.
20. 280 generates the enzymatically active fragment which translocates to the cytosol. J. Biol. Chem., 267: 25396-25401, 1992.
21. Hellman, S., and Vokes, E. E. Advancing current treatments for cancer. Sci. Am., 275:118-123, 1996.
22. Schmidt, M., Hynes, N. E., Groner, B., and Wels, W. A bivalent single-chain antibody-toxin specific for the EGF receptor. Br. J. Cancer. 65: 538-546, 1996.
23. Schmidt, M., and Wels, W. Targeted inhibition of tumour cell growth by a specific single-chain toxin containing an antibody domain and TGFα. Br. J. Cancer, 74: 853-862, 1996.
24. Groner, B., Wick, B., Jeschke, M., Fiegig, H. H., Dengler, W., Runau, T., Mihatsch, M., Kahl, R., Schmidt, M., Wels, W., and Stöcklin, E. Intratumoral application of a heregulin-exotoxin-A fusion protein causes rapid tumor regression without adverse systemic or local effects. Int. J. Cancer, 70: 682-687, 1997.
25. Schmidt, M., Vakalopoulou, E., Schneider, D. W., and Wels, W. Construction and functional characterization of scFv(14E1)-ETA: a novel, highly potent antibody toxin specific for the EGF receptor. Br. J. Cancer, 75: 1575-1584, 1997.
26. Jeschke, M., Wels, W., Dengler, W., Imber, R., Stöcklin, E., and Groner, B. Targeted inhibition of tumor cell growth by recombinant heregulin-toxin fusion proteins. Int. J. Cancer, 60: 730-739, 1995.
27. Fujioka, T., Hasegawa, M., Ogiu, K., Matsushita, Y., Sato, M., and Kubo, T. Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. J. Urol., 155: 1775-1778, 1996.
28. Hillman, G. G., Droz, J. P., and Haas, G. P. Experimental animal models for the study of therapeutic approaches in renal cell carcinoma. In Vivo, 8: 77-80, 1994.
29. Altenschmidt, U., Moritz, D., and Groner, B. Specific cytotoxic T lymphocytes in gene therapy. J. Mol. Med., 75: 259-266, 1997.
30. Gerstmayer, B., Altenschmidt, U., Hoffmann, M., and Wels, W. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB-2 proto-oncogene. J. Immunol., 158: 4584-4590, 1997.